MIRM supply chain intelligence for Mirum Pharmaceuticals, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| PFIZER-INC | PFIZER-INC | 92% | Through the Shire License Agreement, we were assigned the rights to the license agreement ("Pfizer Agreement"), with Pfizer Inc. ("Pfizer"), pursuant to which we obtained an exclusive, worldwide lice… |
| SHIRE | SHIRE | 92% | Through the Shire License Agreement, we were assigned the rights to the license agreement with Pfizer Inc. ("Pfizer"), pursuant to which we obtained an exclusive, worldwide license to Pfizer's know-h… |
| SPECIALTY-PHARMACY | SPECIALTY-PHARMACY | 92% | The Company relies on a single third-party logistics provider ("3PL") and a single specialty pharmacy for all of the Company's sales of its approved medicines in each of the U.S. and Canada as well a… |
| THIRD-PARTY-LOGISTICS-PROVIDER | THIRD-PARTY-LOGISTICS-PROVIDER | 92% | The Company relies on a single third-party logistics provider ("3PL") and a single specialty pharmacy for all of the Company's sales of its approved medicines in each of the U.S. and Canada as well a… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additio… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | Reciprocal relationship from CMMB graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from CMMB graph: Reciprocal relationship from MIRM graph: future, any of which could limit th… |
| MANU | Manchester | 72% | nt will automatically expire on a country-by-country basis upon the expiration of our royalty payment obligations. License Agreement with Sanofi-Aventis Deutschland GmbH Through the Shire License Agr… |
| MANU | Manchester | 72% | Reciprocal relationship from MANU graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from MANU graph: Reciprocal relationship from MIRM graph: nt will automatically expire on a c… |
| ORANY | ORANY | 72% | with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from MIRM graph: with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA… |
| PRQR | ProQR Therapeutics N.V. | 72% | Reciprocal relationship from PRQR graph: Reciprocal relationship from MIRM graph: future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and se… |
| PRQR | ProQR Therapeutics N.V. | 72% | future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additio… |
| SNYNF | Sanofi | 72% | 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risk… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties … |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risk… |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from MIRM graph: 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties t… |
| TVTX | Travere Therapeutics, Inc. | 72% | 808) (“Topic 808”) and determines whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risk… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | USGOV-DEPARTMENT-OF-VETERANS-AFFAIRS | 95% | USAspending awards from Department of Veterans Affairs: $459,591 across 2 awards. 36C25025P0648 PHARMACY PHARMACEUTICAL DRUG; 36C25025P1221 CTESI (CHENODIOL) 250MG DRUG | Qwen corrected direction: Ex… |
| NOVARTIS-PHARMA-AG | NOVARTIS-PHARMA-AG | 85% | ight-of-use asset 1,113 Other non-current assets 3,888 Total assets acquired $ 789,896 Liabilities assumed: Accounts payable 1,589 Accrued expenses and other current liabilities 16,616 Operating leas… |
| NVS | Novartis AG | 85% | Reciprocal relationship from NVS graph: Reciprocal relationship from MIRM graph: ight-of-use asset 1,113 Other non-current assets 3,888 Total assets acquired $ 789,896 Liabilities assumed: Accounts p… |
| CMMB | Chemomab Therapeutics Ltd. | 72% | Reciprocal relationship from CMMB graph: Reciprocal relationship from MIRM graph: with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA … |
| CMMB | Chemomab Therapeutics Ltd. | 72% | with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| ORANY | ORANY | 72% | with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| ORANY | ORANY | 72% | Reciprocal relationship from ORANY graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from ORANY graph: Reciprocal relationship from MIRM graph: with such services. Under certain… |
| PRQR | ProQR Therapeutics N.V. | 72% | with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regula… |
| PRQR | ProQR Therapeutics N.V. | 72% | Reciprocal relationship from PRQR graph: Reciprocal relationship from MIRM graph: with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA … |
| SNYNF | Sanofi | 72% | nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from MIRM graph: nt was recorded for the years end… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | Reciprocal relationship from TKPHF graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from TKPHF graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from TKPH… |
| TKPHF | Takeda Pharmaceutical Company Limited | 72% | nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from MIRM graph: Reciprocal relationship from TVTX g… |
| TVTX | Travere Therapeutics, Inc. | 72% | nt was recorded for the years ended December 31, 2025 and 2024. In April 2023, the Company exercised the Call Option and repurchased all future Revenue Interests. In connection with such repurchase, … |
| CANBRIDGE-PHARMACEUTICALS-INC | CANBRIDGE-PHARMACEUTICALS-INC | 62% | ot paid milestone payments pursuant to this agreement for the periods presented. In May 2022, the Company completed the merger and acquisition of Satiogen for total consideration of approximately $ 2… |
| DART-NEUROSCIENCE-LLC | DART-NEUROSCIENCE-LLC | 62% | ,090 ) Balance at December 31, 2023 $ — $ — The net loss from termination of the RIPA of $ 49.1 million, comprised of the $ 50.2 million loss related to the settlement of the revenue interest liabili… |
| SANOFI-AVENTIS-DEUTSCHLAND-GMBH | SANOFI-AVENTIS-DEUTSCHLAND-GMBH | 62% | d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| SATIOGEN-PFIZER-INC | SATIOGEN-PFIZER-INC | 62% | d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| SHIRE-INTERNATIONAL-GMBH | SHIRE-INTERNATIONAL-GMBH | 62% | d commercialization of the Bile Acid Medicines. The Company paid $ 210.4 million upon closing of the transaction, and up to an additional $ 235.0 million is payable upon the achievement of certain mi… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| MIRM-DEBT | Debt stack $323.8M | 90% | Market cache reports total debt of $323.8M. |
| MIRM-DEBT-10989 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2026-03-31. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| MIRM-OWNER-JANUS-HENDERSON-GROUP-PLC | JANUS HENDERSON GROUP PLC | 90% | 13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 314 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 2 | |
| EDSA | Edesa Biotech, Inc. | 100.00 | 2 | |
| DAWN | Day One Biopharmaceuticals Inc | 100.00 | 2 | |
| AXSM | Axsome Therapeutics, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CSLLY | CSL Limited | 100.00 | 2 | |
| WHWK | Whitehawk Therapeutics, Inc. | 100.00 | 2 | |
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CTMX | CytomX Therapeutics, Inc. | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 |